title: [Safety and immunogenicity of split vaccines of influenza viruses].
abstract: OBJECTIVE
  To evaluate the safety and immunogenicity of influenza split vaccine.
  
  
  METHODS
  According to the criteria of No.2002SL0043, instruction of application for new drug in clinical trial issued by the State Food and Drug Administration, 876 healthy persons were divided at random into vaccine group and control group. The trial was performed with the double blind method. Local and systemic adverse reactions were observed within 3 days after the vaccine group subjects were vaccinated. The antibody response to vaccines was detected with hemagglutination inhibition (HI) test. Numbers of seroconversions and HI titers greater than or equal to 40, as well as the mean geometric titer increase in HI were analyzed.
  
  
  RESULTS
  There was no significant difference in local and systemic adverse reaction between vaccine and control groups. Meanwhile there was also no significant difference in seroconversions and protective level between two groups. However, there was obvious difference in mean geometric titer increase of antibody against H1N1 virus, while there was no significant difference in that of antibodies to H3N2 and type B viruses.
  
  
  CONCLUSIONS
  The safety and immunogenicity of both vaccines are excellent.
authors.affiliation: Changchun Changsheng Life Sciences Limited, Changchun 130012, China.
authors.forename: Chang-lin
authors.initials: CL
authors.lastname: Zhu
authors.forename: Han-hua
authors.initials: HH
authors.lastname: Fang
authors.forename: Feng-cai
authors.initials: FC
authors.lastname: Zhu
authors.forename: Yu-qi
authors.initials: YQ
authors.lastname: Wang
authors.forename: Xiao-li
authors.initials: XL
authors.lastname: Wu
authors.forename: Feng-bo
authors.initials: FB
authors.lastname: Xue
authors.forename: Yan-jie
authors.initials: YJ
authors.lastname: Shen
authors.forename: Jin-zhang
authors.initials: JZ
authors.lastname: Lian
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005334:Fever / Q000139:chemically induced; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007223:Infant; D009980:Influenza A virus / Q000276:immunology*; D009981:Influenza B virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000009:adverse effects / Q000145:classification / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control*; D008875:Middle Aged; D012449:Safety; D015164:Vaccines, Inactivated / Q000009:adverse effects / Q000145:classification / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D007252:Influenza Vaccines; D015164:Vaccines, Inactivated